PINNACLE研究:尼洛替尼联合聚乙二醇干扰素α2b治疗初诊慢性期慢性髓性白血病的多中心II期试验
澳大利亚白血病与淋巴瘤工作组CML11(Pinnacle)II期研究评估尼洛替尼联合聚乙二醇干扰素α2b(peg-IFNα)的耐受性与疗效。60例初诊慢性期CML患者起始尼洛替尼300mg每日两次,3个月起加用peg-IFNα 30-50μg/周至24个月。中位随访60个月,12个月MMR累积发生率87%,24和60个月MR4.5发生率分别为55%和82%。
要点
- 12个月MMR累积发生率87%,60个月MR4.5发生率82%
- 58%和35%患者分别接受≥50%和≥85%的peg-IFNα计划剂量
核心结论
- 尼洛替尼联合peg-IFNα在初诊慢性期CML中产生高比例分子学缓解,耐受性与既往研究相似。
研究设计与样本
- 多中心II期试验(ANZCTRN12612000851864),60例初诊慢性期CML患者,中位年龄48.5岁(范围19-72),45%为女性。
- 尼洛替尼300mg每日两次起始,3个月起加用皮下peg-IFNα 30-50μg/周至24个月(按耐受性调整)。
主要发现
- 中位随访60个月,40例(67%)仍在研究中。
- 12个月MMR(BCR::ABL1≤0.1%)累积发生率为87%;24和60个月MR4.5(BCR::ABL1≤0.0032%)发生率分别为55%和82%。
- peg-IFNα停药常见原因为情绪障碍(5例)、甲状腺疾病(4例)和肌痛(4例)。
关键数值与推荐
- 58%患者接受≥50%的peg-IFNα计划剂量,35%接受≥85%的计划剂量。
临床怎么用
- 尼洛替尼联合peg-IFNα可作为初诊慢性期CML的治疗选择之一,需关注情绪、甲状腺及肌肉相关不良反应。
- 部分深度分子学缓解患者可尝试TFR,但需密切监测。
局限性
- 单臂II期研究,样本量60例,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the tolerability and efficacy of pegylated interferon alfa-2B (peg-IFNα; PegIntron, MSD) combined with nilotinib in the Australasian Leukaemia and Lymphoma Group CML11 (Pinnacle) study. This phase II study started patients on nilotinib 300 mg twice daily. Subcutaneous peg-IFNα was added at 30-50 50 μg/week from 3 months until 24 months as tolerated. Sixty patients were enrolled with a median age of 48.5 years (range 19-72); 45% were female. With a median follow-up of 60 months, 40 patients (67%) remain on study. The proportion of patients who received ≥50% and ≥85% of their assigned peg-IFNα doses were 58% and 35% respectively. Common reasons for peg-IFNα discontinuation were mood disturbance (5), thyroid disease (4) and myalgia (4). The cumulative incidence of Major Molecular Response (MMR, BCR::ABL1≤0.1%) was 87% by 12 months; Molecular Response 4.5 (MR4.5, BCR::ABL1≤0.0032%) incidence at 24 and 60 months was 55% and 82% respectively. Thirty-seven patients (62%) had MR4.5 for >24 months, 14 of whom attempted treatment-free remission (TFR); 13 remained in TFR at a median follow-up of 32 months. CML11 demonstrated that peg-IFNα with nilotinib leads to high rates of molecular response, with tolerability similar to prior studies. Trial registration ANZCTRN12612000851864.
引用
- Yeung DT, Grigg AP, Reynolds J, et al. The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2025. PMID: 41431370. doi:10.1111/bjh.70276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。